Aqueous Pharmaceutical Formulation of Hydrocortisone Sodium Phosphate and Monothioglycerol

The USPTO published patent application US20260091042A1 for Antares Pharma, Inc. disclosing aqueous formulations comprising hydrocortisone sodium phosphate and monothioglycerol as an antioxidant. The formulations may further include buffer components such as monobasic sodium phosphate, dibasic sodium phosphate, or disodium EDTA. The application also covers methods of treating diseases or disorders by administering these formulations. Application number 19413640 was filed December 9, 2025 and published April 2, 2026.

This publication represents routine intellectual property protection activity by Antares Pharma in the pharmaceutical formulation space. The patent application does not create new regulatory obligations for other entities. Competitors developing similar steroid phosphate formulations should review the pending claims to assess potential freedom-to-operate considerations once the application proceeds to grant. No immediate compliance actions are required.